FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:1738-1749 October 30, 2003 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Schizophrenia is a chronic, debilitating psychotic mental disorder that affects about 1 percent of people. A new generation of medications and recent developments in neuropathology, brain imaging, and molecular genetics have led to a greater understanding of the pathophysiology of schizophrenia and to improved treatment. Nonetheless, it remains an enigmatic illness that places a substantial burden on patients, their families, and society.

Clinical Characteristics

Schizophrenia has varied and ominous symptoms that generally begin in late adolescence or early adulthood and usually continue throughout life.¹ Most patients have a history of behavioral dysfunction — primarily social and learning difficulties.² Diagnostic features of schizophrenia . . . [Full Text of this Article]

Pathophysiology

Schizophrenia and Dopamine

Evidence of Multiple Types of Brain Dysfunction

Genetic Findings in Schizophrenia

Pathophysiology and Pharmacologic Treatment

Antipsychotic Treatment

First-Generation Antipsychotic Agents

            Efficacy

            Side Effects

Second-Generation Antipsychotic Agents

            Clozapine

            Newer Second-Generation Agents

            Side Effects

            Cognitive Improvement

Treatment Guidelines

Treatment of a First Psychotic Episode

Maintenance Treatment

Indications for Clozapine

The Role of First-Generation Antipsychotic Agents

The Choice of an Antipsychotic Drug

Early Intervention

Source Information

From the Institute for Children's Mental Disorders, University of Colorado and the Veterans Affairs Medical Center, Denver.

Address reprint requests to Dr. Freedman at the Department of Psychiatry, C-268-71, University of Colorado Health Sciences Center, Denver CO 80262, or at robert.freedman@uchsc.edu.

Related Letters:

Schizophrenia, Drug Therapy, and Monitoring
Bradford D. W., Stroup T. S., De Socio G. V. L.
Extract | Full Text | PDF  
N Engl J Med 2004; 350:415-416, Jan 22, 2004. Correspondence

This article has been cited by other articles:

• Akkaya, C, Kaya, B, Kotan, Z, Sarandol, A, Ersoy, C, Kirli, S (2009). Hyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; three cases. J Psychopharmacol 23: 723-726 [Abstract]  
• Shoenfeld, N., Ulman, A.-M., Weiss, M., Strous, R. D. (2008). Best Practices: To Lock or Not to Lock Patients'Rooms: The Key to Autonomy?. Psychiatr. Serv. 59: 1100-1102 [Abstract] [Full Text]  
• Soumerai, S. B., Zhang, F., Ross-Degnan, D., Ball, D. E., LeCates, R. F., Law, M. R., Hughes, T. E., Chapman, D., Adams, A. S. (2008). Use Of Atypical Antipsychotic Drugs For Schizophrenia In Maine Medicaid Following A Policy Change. Health Aff (Millwood) 27: w185-w195 [Abstract] [Full Text]  
• Erickson, S. K., Ciccone, J. R., Schwarzkopf, S. B., Lamberti, J. S., Vitacco, M. J. (2007). Legal Fallacies of Antipsychotic Drugs. J Am Acad Psychiatry Law 35: 235-246 [Abstract] [Full Text]  
• Cooper, G.D., Pickavance, L.C., Wilding, J.P.H., HarroLd, J.A., HaLford, J.C.G., Goudie, A.J. (2007). Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. J Psychopharmacol 21: 405-413 [Abstract]  
• Vanover, K. E., Robbins-Weilert, D., Wilbraham, D. G., Mant, T. G. K., van Kammen, D. P., Davis, R. E., Weiner, D. M. (2007). Pharmacokinetics, Tolerability, and Safety of ACP-103 Following Single or Multiple Oral Dose Administration in Healthy Volunteers. J Clin Pharmacol 47: 704-714 [Abstract] [Full Text]  
• Bjarnadottir, M., Misner, D. L., Haverfield-Gross, S., Bruun, S., Helgason, V. G., Stefansson, H., Sigmundsson, A., Firth, D. R., Nielsen, B., Stefansdottir, R., Novak, T. J., Stefansson, K., Gurney, M. E., Andresson, T. (2007). Neuregulin1 (NRG1) Signaling through Fyn Modulates NMDA Receptor Phosphorylation: Differential Synaptic Function in NRG1+/- Knock-Outs Compared with Wild-Type Mice. J. Neurosci. 27: 4519-4529 [Abstract] [Full Text]  
• Buie, L. W, Oertel, M. D, Cala, S. O (2006). Allopurinol as Adjuvant Therapy in Poorly Responsive or Treatment Refractory Schizophrenia. The Annals of Pharmacotherapy 40: 2200-2204 [Abstract] [Full Text]  
• Roberts, L. W., Warner, T. D., Hammond, K. G., Dunn, L. B. (2006). Assessments by Patients With Schizophrenia and Psychiatrists of Relative Risk of Research Procedures. Psychiatr. Serv. 57: 1629-1635 [Abstract] [Full Text]  
• INGMAN, K., KUPILA, J., HYYTIA, P., KORPI, E. R. (2006). EFFECTS OF ARIPIPRAZOLE ON ALCOHOL INTAKE IN AN ANIMAL MODEL OF HIGH-ALCOHOL DRINKING. Alcohol Alcohol 41: 391-398 [Abstract] [Full Text]  
• Honer, W. G., Thornton, A. E., Chen, E. Y.H., Chan, R. C.K., Wong, J. O.Y., Bergmann, A., Falkai, P., Pomarol-Clotet, E., McKenna, P. J., Stip, E., Williams, R., MacEwan, G. W., Wasan, K., Procyshyn, R., the Clozapine and Risperidone Enhancement (CARE) S, (2006). Clozapine Alone versus Clozapine and Risperidone with Refractory Schizophrenia. NEJM 354: 472-482 [Abstract] [Full Text]  
• PARK, S., ROSS-DEGNAN, D., ADAMS, A. S., SABIN, J., KANAVOS, P., SOUMERAI, S. B. (2005). Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: Population-based study. Br. J. Psychiatry 187: 137-142 [Abstract] [Full Text]  
• Easton, R. M., Cho, H., Roovers, K., Shineman, D. W., Mizrahi, M., Forman, M. S., Lee, V. M.-Y., Szabolcs, M., de Jong, R., Oltersdorf, T., Ludwig, T., Efstratiadis, A., Birnbaum, M. J. (2005). Role for Akt3/Protein Kinase B{gamma} in Attainment of Normal Brain Size. Mol. Cell. Biol. 25: 1869-1878 [Abstract] [Full Text]  
• Kovoor, A., Seyffarth, P., Ebert, J., Barghshoon, S., Chen, C.-K., Schwarz, S., Axelrod, J. D., Cheyette, B. N. R., Simon, M. I., Lester, H. A., Schwarz, J. (2005). D2 Dopamine Receptors Colocalize Regulator of G-Protein Signaling 9-2 (RGS9-2) via the RGS9 DEP Domain, and RGS9 Knock-Out Mice Develop Dyskinesias Associated with Dopamine Pathways. J. Neurosci. 25: 2157-2165 [Abstract] [Full Text]  
• (2004). Much Room for Improvement in Antipsychotic Drug Therapy for Schizophrenia. JWatch Neurology 2004: 7-7 [Full Text]  
• (2004). Reviews of Note. JWatch Psychiatry 2004: 10-10 [Full Text]  
• Bradford, D. W., Stroup, T. S., De Socio, G. V. L. (2004). Schizophrenia, Drug Therapy, and Monitoring. NEJM 350: 415-416 [Full Text]